Literature DB >> 19248230

Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.

Arik Dahan1, Gordon L Amidon.   

Abstract

The purpose of this study was to investigate the role of P-gp efflux in the in vivo intestinal absorption process of BCS class III P-gp substrates, i.e. high-solubility low-permeability drugs. The in vivo permeability of two H (2)-antagonists, cimetidine and famotidine, was determined by the single-pass intestinal perfusion model in different regions of the rat small intestine, in the presence or absence of the P-gp inhibitor verapamil. The apical to basolateral (AP-BL) and the BL-AP transport of the compounds in the presence or absence of various efflux transporters inhibitors (verapamil, erythromycin, quinidine, MK-571 and fumitremorgin C) was investigated across Caco-2 cell monolayers. P-gp expression levels in the different intestinal segments were confirmed by immunoblotting. Cimetidine and famotidine exhibited segmental dependent permeability through the gut wall, with decreased P(eff) in the distal ileum in comparison to the proximal regions of the intestine. Coperfusion of verapamil with the drugs significantly increased the permeability in the ileum, while no significant change in the jejunal permeability was observed. Both drugs exhibited significantly greater BL-AP than AP-BL Caco-2 permeability, indicative of net mucosal secretion. Concentration dependent decrease of this secretion was obtained by the P-gp inhibitors verapamil, erythromycin and quinidine, while no effect was evident by the MRP2 inhibitor MK-571 and the BCRP inhibitor FTC, indicating that P-gp is the transporter mediates the intestinal efflux of cimetidine and famotidine. P-gp levels throughout the intestine were inversely related to the in vivo permeability of the drugs from the different segments. The data demonstrate that for these high-solubility low-permeability P-gp substrates, P-gp limits in vivo intestinal absorption in the distal segments of the small intestine; however P-gp plays a minimal role in the proximal intestinal segments due to significant lower P-gp expression levels in this region.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19248230     DOI: 10.1021/mp800088f

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  28 in total

1.  Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir.

Authors:  Jonathan M Miller; Arik Dahan; Deepak Gupta; Sheeba Varghese; Gordon L Amidon
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

Review 2.  The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs.

Authors:  Arik Dahan; Jonathan M Miller
Journal:  AAPS J       Date:  2012-03-06       Impact factor: 4.009

Review 3.  The role of transporters in the pharmacokinetics of orally administered drugs.

Authors:  Sarah Shugarts; Leslie Z Benet
Journal:  Pharm Res       Date:  2009-06-30       Impact factor: 4.200

4.  Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements.

Authors:  Caroline A Larregieu; Leslie Z Benet
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

5.  Exploring the Feasibility of Biowaiver Extension of BCS Class III Drugs with Site-Specific Absorption Using Gastrointestinal Simulation Technology.

Authors:  Le Sun; Jin Sun; Zhonggui He
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

6.  Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification.

Authors:  Tuba Incecayir; Yasuhiro Tsume; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-02-04       Impact factor: 4.939

7.  Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.

Authors:  Olena Kis; Jason A Zastre; Md Tozammel Hoque; Sharon L Walmsley; Reina Bendayan
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

8.  The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.

Authors:  Arik Dahan; Avital Beig; Viktoriya Ioffe-Dahan; Riad Agbaria; Jonathan M Miller
Journal:  AAPS J       Date:  2012-12-15       Impact factor: 4.009

9.  Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine.

Authors:  Moran Fairstein; Rotem Swissa; Arik Dahan
Journal:  AAPS J       Date:  2013-02-26       Impact factor: 4.009

10.  Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.

Authors:  Arik Dahan; Gordon L Amidon
Journal:  Pharm Res       Date:  2008-12-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.